ReviewChemMedChem2026
Xanthones and Their Nitrogen and Sulfur Analogs in Alzheimer's Disease: Recent Progress Toward Multifunctional Therapeutics.
Review in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder and the leading cause of dementia among the elderly worldwide. In medicinal chemistry and drug discovery, heterocycles are widely recognized as privileged scaffolds due to their structural versatility and biological relevance. In the context of AD, heterocyclic compounds have been extensively investigated for the development of potential therapeutic agents. Among fused heterocyclic systems, oxygen-, nitrogen-, and sulfur-containing heterocycles are particularly prominent in approved drugs. This review focuses on recent advances in the exploration of xanthone derivatives, alongside with their nitrogen- and sulfur-containing analogs, as promising template scaffolds for the development of prospective anti-AD therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.